Navigation Links
ChanTest to Highlight the World's Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
Date:9/18/2008

Company CEO is featured speaker: "Case Study - Screening Ion Channels for

Safety and Efficacy" on Friday, September 26 at 11:30

CLEVELAND, Sept. 18 /PRNewswire/ -- ChanTest will feature its expanding line of ion channel services and cell lines for drug-discovery and development applications in booth 11 at the Assays and Cellular Targets conference in San Diego, September 24-26. ChanTest designed its ion channel cell lines and services to provide drug-discovery researchers the early information they need to identify the most promising target compounds and eliminate those that could ultimately cause harmful side effects. ChanTest is also working with pharmaceutical and biotech companies to help rescue shelved pharmaceutical compounds.

Dr. Arthur (Buzz) Brown, ChanTest's founder and CEO, will present a case study to conference participants entitled, "Screening Ion Channels for Safety and Efficacy," on Friday, September 26 at 11:30, as part of the conference's Ion Channel Targets track. "We are developing a library of ion channel-expressing cell lines for screening with the full range of automated patch clamp instruments and FLIPR-Tetra(r)," said Dr. Brown. "At present, 86 'books' are available and 160 will be available by June 2009. We validate each cell line for cDNA sequence, Western blot, voltage range, gating, and pharmacology. We recognize that each research program has its own unique needs and priorities, so we've designed our services and cell lines to offer the most flexibility possible. Our validated ion channels can be mixed and matched into panels according to tissue, e.g., cardiac; therapeutic area, e.g., pain; and ion channel family, e.g., TRP channels. And we draw upon our years of ion channel experience to help customers design an appropriate testing program to meet their specific scientific and budgetary goals."

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

The A/C/T Assays and Cellular Targets conference and exhibition takes place September 24-26, 2008 at the Marriott San Diego Hotel & Marina in California.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines - the most comprehensive in the world. Since its inception in 1998, ChanTest has tested more than 18,000 compounds for more than 250 global pharmaceutical and biotech companies - helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit http://www.chantest.com.


'/>"/>
SOURCE ChanTest
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
2. ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
3. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 839
4. ChanTest Launches Redesigned Web Site
5. ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104
6. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
9. Neuralstem Reports Second Quarter Financial Results and Highlights
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the leader in ... its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), ... Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in ...
(Date:5/3/2016)... ... May 03, 2016 , ... Wearable ... and data driven conferences, will take place on June 7-8, 2016, at the New York ... Raman-Tangella on incorporating technology -- including AR/VR, machine learning, apps, robotics and AI -- ...
(Date:5/3/2016)...  Dr. Thomas P. McHugh , an internationally ... Woodlands, Texas , now offers SculpSure, the new ... cells in just 25-minutes, leaving a slimmer figure for ... Americans report feeling bothered by excess weight and are ... a growing industry. This innovative new approach to non-invasive ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nashville ... IVF laboratories. A contingency of reproductive endocrinologists, including Dr. George Hill ... infertility and to help them build families. , Ovation Fertility is a nationwide ...
Breaking Biology Technology:
(Date:3/10/2016)... 10, 2016   Unisys Corporation (NYSE: UIS ... (CBP) is testing its biometric identity solution at the ... to help identify certain non-U.S. citizens leaving the country. ... designed to help determine the efficiency and accuracy of using ... and will run until May 2016. --> ...
(Date:3/9/2016)... -- Nigeria . Recently, the ... public service employees either did not exist with their ...    --> Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> DERMALOG, the biometrics innovation ...
(Date:3/8/2016)... RALEIGH, N.C. , March 8, 2016 /PRNewswire/ ... biometric sensor technology, today announced it has secured ... led by GII Tech, a new venture fund ... LLC, with additional participation from existing investors TDF ... use the funds to continue its triple-digit growth ...
Breaking Biology News(10 mins):